Add To Watchlist
Share URL
About The Company
CEO
Mr. Bryan C. Hanson
Market Cap
24.92 Billion USD
Sector
Healthcare
Website
https://www.zimmerbiomet.comLast Update
2/22/2024, 12:00:00 PM
Description
Zimmer Biomet Holdings, Inc.
Read More
Overview
Value
35
Growth
14
Health
73
Management
37
Analyst Opinion
89
Total
50
All Scores Out Of 100
Best Features
- Earnings growth has improved recently
- Has a low level of debt
- Low risk of bankruptcy
- Has strong financial health
- Liked by analysts
- Low preportion of income is paid as dividend
Risk Factors
- There is a history of diluting shareholders
- No margin of safety at their current market price
- Disliked by Twitter users
- Poor earnings and cashflow growth
- Price-to-earnings ratio of 25.8 is higher than the market average (19.6x)
Market Peers
ZBH
Key Figures
PE Ratio (TTM)
25.83
Margin Of Safety (DCF)
-6.93%
Revenue Growth (5 Year Average)
1.00%
Ratings Consensus
Strong Buy
Share Buybacks
-0.75%
Dividend Yeild (TTM)
0.76%
Valuation
Value Score
35
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Buy Target: < 127.5 USD ✔
Current Price: 126.6 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.
Price/Earnings
25.83x
Free Cashflow Yeild
4.26%
PE/Earnings Growth
N/A
Price/Book
2.12x
Growth
Growth Score
14
- ✔ Revenue growth has improved this yeara
- ✔ Earnings growth has improved this year
- ✔ Free Cashflow growth has improved this year
- ✘ 5 Year Average Revenue growth of 1.00% is lower than the market average (10.97%)
- ✘ 5 Year Average Earnings growth of -8.80% is lower than the market average (14.48%)
- ✘ 5 Year Average Free Cashflow growth of 1.56% is lower than the market average (12.35%)
Revenue Growth
1.00%
Earnings Growth
-8.80%
Cashflow Growth
1.56%
Health
Health Score
73
Altman Z Score
3.10
Piostroski Score
8.00
Debt/Equity
0.47x
Current Assets/Liabilities
8.13x
Free Cashflow/Total Debt
0.21x
Debt/Capital
1.29x
Dividend
Secure Dividend Score
60
- ✔ Dividend is likely safe
- ✔ Long term dividend payout ratio of -7.90% is considered good
- ✔ Payout ratio (TTM) of 19.62% is lower than the average (40%)
- ✔ Dividends have shown growth over the last 5 years
- ✘ Dividend yeild of 0.76% is less than the market average (1.85%)
- ✘ Dividend growth has been slowing recently
- ✘ Spending a higher percentage of their income on dividends than last 5 years
Dividend Yeild
0.76%
Dividend Growth
0.55%
Payout Ratio (Earnings)
19.62%
Payout Ratio (Cashflow)
17.85%
Management
Management Score
37
- ✔ Has issued new shares to finance growth when share price is high
- ✔ Return-on-capital-employed of 11.20% is higher than the market average (10%)
- ✘ Has a history of diluting shareholders to finance activity
- ✘ Has returned higher dividends when earnings have fallen
- ✘ Return-on-equity of 2.41% is lower than the market average (15%)
Average Buybacks/Dilution
-0.75%
Recent Buybacks/Dilution
-0.39%
5 Year Price Volitility
13.52%
Return On Assets
1.38%
Return On Capital Employed
11.20%
Return On Equity
2.41%
Return On Free Cashflow
N/A
Return On Investments
N/A
Analysts
Analyst Opinion
89
- ✔ Ratings consensus is Strong Buy
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
Other Information
Company Name
Zimmer Biomet Holdings, Inc.
Currency
USD
Beta
1.02254
Vol Avg
1449054
Ceo
Mr. Bryan C. Hanson
Cik
0001136869
Cusip
98956P102
Exchange
New York Stock Exchange
Full Time Employees
18000
Industry
Medical Devices
Sector
Healthcare
Ipo Date
2001-07-25
Address
345 East Main Street
City
Warsaw
State
IN
Country
US
Zip
46580
Phone
574 267 6131
Analysis Last Updated
2/22/2024, 12:00:00 PM
All financial data provided by FMP
Social Sentiment
Social Sentiment Score
0
Twitter Sentiment
N/A
Stocktwits Sentiment
N/A